Diabetic Neuropathic Pain-Pipeline Insights, 2015 - A DelveInsight’s Report

DelveInsight, the leading market research and consulting company has added a new report “Diabetic Neuropathic Pain-Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight.
 
NEW DELHI - Oct. 19, 2015 - PRLog -- DelveInsight, the leading market research and consulting company has added a new report “Diabetic Neuropathic Pain-Pipeline Insights, 2015” to its portfolio.With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date information of market till the date of order.

The report “Diabetic Neuropathic Pain-Pipeline Insights, 2015 provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

• The information of around 55 pipeline drugs with 40+ companies involved in drug development. There are 2 drugs in Phase III, 10 in Phase II, 3 in Phase I,   6 in pre-clinical , 1 discoverey,  12 discontinued and 21 dormant drugs.

• Mirogabalin developed by Daichi Sankyo and Clonidine developed by Bio Delivery Sciences International is under Phase III clinical trial.

• R&D activities and technologies used along with the pipeline molecules in development

•  Stages of development of pipeline molecules.

• Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

• Information related to collaborations, in-licensing and out-licensing deals.

DelveInsight’s, “Diabetic Neuropathic Pain-Pipeline Insights, 2015” report provides the in-depth analysis of the pipeline assets across the Diabetic Neuropathic Pain. Therefore the report on “Diabetic Neuropathic Pain-Pipeline Insights, 2015” provides information on chemical technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email atinfo@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making, identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Contact
DelveInsight Business Research
***@delveinsight.com
End
Source: » Follow
Email:***@delveinsight.com Email Verified
Tags:DelveInsight, Mirogabalin, Clonidine
Industry:Marketing
Location:New Delhi - Delhi - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
DelveInsight PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share